Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Elsevier Business Intelligence

12:47 EST 16th December 2018 | BioPortfolio

Here are the most relevant search results for "Elsevier Business Intelligence" found in our extensive news archives from over 250 global news sources.

More Information about Elsevier Business Intelligence on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Elsevier Business Intelligence for you to read. Along with our medical data and news we also list Elsevier Business Intelligence Clinical Trials, which are updated daily. BioPortfolio also has a large database of Elsevier Business Intelligence Companies for you to search.

Showing News Articles 1–25 of 1,700+ from Elsevier Business Intelligence

Friday 14th December 2018

Aveo and AstraZeneca enter trial collaboration

Aveo Pharmaceuticals Inc. (Aveo Oncology) and AstraZeneca PLC are working together to evaluate the combination of Aveo’s Fo...

The Medicines Co. nets $144.9mm in convertible debt financing

The Medicines Co. netted $144.9mm (gross $150mm) through the private sale of 3.50% convertible senior notes due 2024 to quali...

Public offering nets $51.7mm for Fluidigm

Fluidigm Corp. (microfluidics and other research products) netted $51.7mm through a public offering of 8.15mm common shares a...

Tocagen nets $28.2mm through public offering

Tocagen Inc. (developing cancer-selective gene therapies) netted $28.2mm through a public offering of 3mm common shares at $1...

EU Drug Filings To Fall Slightly In 2019, But Scientific Advice On The Up

The EMA expects initial applications for drug approvals to decline slightly next year, with the budget also down a little...&...

Two Orphans And An Avastin Biosimilar Among EU Approval Recommendations

Seven new drug applications got the thumbs up this week from the EMA's drug evaluation committee, the CHMP.  Their E...

Thursday 13th December 2018

Ra Pharmaceuticals nets $122.2mm in FOPO

Ra Pharmaceuticals Inc. netted $122.2mm in a follow-on public offering of 8.4mm common shares at $15.50. The company plans t...

Checkmate brings in $22mm through Series C round

Oncology immunotherapy developer Checkmate Pharmaceuticals Inc. raised $22mm through what appears to be its Series C round. N...

OrthoPediatrics nets $43.8mm via FOPO

Implants developer OrthoPediatrics Corp. netted $43.8mm through a follow-on public offering of 1.7mm common shares (including...

EDGe Surgical gets $4.3mm in Series A

EDGe Surgical Inc. (devices for orthopedic surgery) raised $4.3mm in its Series A round to angels. According to the Form D, 2...

Synthorx completes $140mm initial public offering

Synthorx Inc. (synthetic biology for protein therapeutics development) netted $140mm through its initial public offering of 1...

Series B lands $70mm for Akero

Just six months after its $65mm Series A financing, Akero Therapeutics Inc. has now raised $70mm through a Series B round led...

AC Immune partners with Lilly for Alzheimer's treatments in $1.9bn deal

Eli Lilly & Co. and AC Immune SA have joined forces in a new multi-year deal focused on tau aggregation inhibitors for Alzhei...

Bausch initiates stalking horse bid process for Synergy Pharma

Concurrent with filing for Chapter 11, Synergy Pharmaceuticals Inc. signed a definitive agreement under a court-supervised st...

EMA Clarifies Sponsor Role In Contracting For Investigator Sites

The European Medicines Agency has made it clear that all clinical trial-related medical activities are the responsibility of ...

UK Inquiry Into ‘Unfair’ Orkambi Pricing Risks Pricing Confidentiality

The UK government has criticized Vertex for the company’s approach to pricing its cystic fibrosis drug Orkambi. In the mean...

Wednesday 12th December 2018

US FDA Tightly Controls Meetings With Generic Sponsors After Complete Response Letters

The meetings are intended to help sponsors understand deficiencies and FDA will make sure they stay on topic.  ...

Roche And Shionogi Aim For EU Accelerated Assessment

Roche will learn this week if two potential anticancer it is developing - polatuzumab vedotin and entrectinib - will be......

Tanzanian Drugs Regulator Wins WHO Performance Accolade

The Tanzanian medicines agency has obtained a “level 3” ranking from the WHO, meaning it now runs a “stable, well......

Tuesday 11th December 2018

WhiteSwell closes $30mm Series B

Cardiovascular-focused WhiteSwell raised $30mm in its Series B financing led by RA Capital Management and an InCube Ventures ...

Bay Labs, Edwards team up in cardiovascular disease detection

Bay Labs Inc. and Edwards Lifesciences Corp. are teaming up to use artificial intelligence (AI) to develop better ways to det...

DiaMedica nets $15.33mm in Nasdaq IPO

In its initial public offering on the Nasdaq exchange, TSX-traded DiaMedica Therapeutics Inc. (recombinant protein drug devel...

Public offering nets $141mm for Global Blood Therapeutics

Global Blood Therapeutics Inc. netted $141mm through a public offering of 3.4mm common shares at $44. The company is developi...

Moderna nets $571.1mm in IPO

In its initial public offering on Nasdaq, Moderna Inc. (messenger RNA (mRNA) therapeutics) netted $571.1mm through the sale o...

CHMP Delays Review of Portola's Ondexxya; Who Will Pass Muster?

With its final meeting of the year under way, the EMA's medicines evaluation committee, the CHMP, will bring seasonal che...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks